EQUIPIN Drug Patent Profile

When do Equipin patents expire, and when can generic versions of Equipin launch?

Equipin is a drug marketed by Mission Pharma and is included in one NDA.

The generic ingredient in EQUIPIN is homatropine methylbromide. There are five drug master file entries for this compound. Additional details are available on the homatropine methylbromide profile page.

Summary for EQUIPIN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	45
DailyMed Link:	EQUIPIN at DailyMed

US Patents and Regulatory Information for EQUIPIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mission Pharma	EQUIPIN	homatropine methylbromide	TABLET, CHEWABLE;ORAL	086310-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: June 14, 2026

EQUIPIN (Pharmaceutical) Market Dynamics and Financial Trajectory: Sales Trends, Competitive Pressure, and Exclusivity/Patent Timeline

EQUIPIN’s market dynamics and financial trajectory hinge on three drivers: (1) time remaining to key regulatory exclusivities and patent expirations for the active ingredient and any listed Orange Book compounds, (2) the rate at which FDA-approved competitors (including generics) enter with AB-rated labels, and (3) payer and channel mix shifts that determine net price versus gross sales. Without a verified product dossier (active ingredient, NDA/BLA number(s), strength/formulation, launch market, and FDA approval history), the only accurate conclusion is that a complete financial trajectory cannot be produced from the provided prompt.

What is EQUIPIN and how is it positioned in the pharma market?

Featured snippet: EQUIPIN positioning depends on the active ingredient, indication(s), dosage form, and payer contracting benchmarks, which determine whether the product competes on clinical differentiation or price.

Which active ingredient and indication does EQUIPIN cover?

Market segmentation for a prescription medicine is determined by:

• FDA-approved indication(s) and line of therapy
• Route of administration (oral, injectable, topical, etc.)
• Specialty vs. primary care distribution
• Off-label vs. labeled utilization patterns

How does channel mix affect EQUIPIN net sales?

Key market dynamics that typically explain net sales movement:

• Wholesale and specialty pharmacy penetration
• Contracting intensity with PBMs and IDNs
• Rebate and copay assistance structures
• Inventory timing around generic entry windows

How does EQUIPIN’s sales performance typically track with exclusivity and entry risk?

Featured snippet: Sales usually flatten when payer coverage becomes restrictive or when competitive threats intensify; they then decline after generic launches, typically with a steep first-year fall.

What patents protect EQUIPIN and what is the expiration profile?

A defensible patent-driven trajectory requires:

• Orange Book listing(s) tied to EQUIPIN’s NDA/BLA
• Patent numbers, assignees, and expiration dates
• Any regulatory exclusivity offsets (new chemical entity, new therapeutic indication, pediatric exclusivity)

When does EQUIPIN lose exclusivity and generics become likely?

Generic timing is usually governed by:

• Primary patent expiry
• Any “carve-out” pediatric extensions
• Orange Book “blocking” patents and their lifetimes
• Paragraph IV filing windows and settlement-triggered entry dates

What is the Orange Book status of EQUIPIN?

Featured snippet: Orange Book status determines whether ANDA filers can launch at-risk or must wait for patent expiry or litigation resolution.

Which patents are listed for EQUIPIN’s NDA/BLA?

Orange Book listing structure normally includes:

• Drug substance or drug product patents
• Formulation patents
• Method-of-use patents (indication-specific)
• Salts, polymorphs, particle-size, and controlled-release patents

Are there method-of-use patents that could extend exclusivity after formulation expiry?

Indication-specific method-of-use claims can delay generic entry even when drug product patents expire, depending on label carve-outs and FDA labeling carve-out acceptance.

Which companies compete with EQUIPIN and how does pricing pressure develop?

Featured snippet: Competitor entry reshapes net price quickly, first through “market share capture” by low-cost alternatives and then through sustained rebate pressure.

What generic or biosimilar risks exist for EQUIPIN?

If EQUIPIN is a small-molecule drug, the generic risk is driven by:

• ANDA acceptance and tentative approval
• “Skinny label” scenarios and carve-out feasibility
• Launch readiness of manufacturing sites

If EQUIPIN is biologic, the risk becomes biosimilar-specific:

• BLA/BLA pathway
• interchangeability timelines
• REMS or administration ecosystem constraints

What Paragraph IV challenges are filed against EQUIPIN?

Featured snippet: The number and type of Paragraph IV certifications predict the entry timeline more accurately than generic filing announcements alone.

How do settlements typically affect EQUIPIN generic entry dates?

Settlement patterns often include:

• Agreed launch dates
• License fees or royalty structures
• Niche carve-outs that preserve brand share
• “Non-at-risk” commitments for the challenger

What litigation outcomes drive fastest erosion of EQUIPIN sales?

The largest sales impacts usually follow:

• Early adverse rulings (invalidity or non-infringement)
• Consent judgments tied to expiry triggers
• Skinny label acceptance with minimal label restrictions

How does EQUIPIN’s financial trajectory differ across US vs ex-US markets?

Featured snippet: Brand-to-generic conversion schedules differ by jurisdiction, and ex-US share can cushion US declines or expose the brand to faster erosion.

Which regulatory pathways shape growth outside the US?

Typical drivers:

• Local equivalents of Orange Book or patent linkage
• Reimbursement tiers
• Tender dynamics and national formularies

Does EQUIPIN face faster generic entry internationally?

International dynamics often diverge based on:

• Patent coverage strength in specific countries
• Generic filing and approval lead times
• Local enforcement and litigation costs

What formulation, manufacturing, and IP barriers could block or delay generic entry for EQUIPIN?

Featured snippet: Formulation and manufacturing-method claims can slow ANDA approvals or force design-around changes that delay launch.

Which formulation patents usually matter most?

For brands, the highest practical barrier patents often include:

• Controlled-release profiles
• Stability and shelf-life systems
• Particle engineering or solid-state form claims
• Bioavailability-related drug product patents

How do manufacturing know-how barriers affect competitive timelines?

Even after regulatory approval, commercial launch depends on:

• Supply chain readiness
• Scale-up comparability
• Quality system maturity and inspection outcomes

How does EQUIPIN compare with therapeutic alternatives on clinical and commercial metrics?

Featured snippet: Competitive outcomes depend on comparative effectiveness, safety, administration burden, and payer preference rules.

What differentiates EQUIPIN vs. same-class drugs?

Common differentiators that impact adoption and retention:

• Dosing frequency and titration burden
• Adverse event profile and contraindication scope
• Prescriber experience and patient support programs
• Demonstrated adherence improvements for oral regimens

How do switching dynamics usually affect EQUIPIN revenue?

Revenue pressure arises from:

• PBM step-therapy rules
• Guideline updates favoring alternative mechanisms
• Post-market safety or labeling changes that reduce eligible patient pools

What does the financial trajectory likely look like around generic entry for EQUIPIN?

Featured snippet: Net sales typically show a multi-phase decline: stable period pre-entry, sharp drop at first generic launch, then further erosion driven by penetration and price compression.

Typical revenue curve components for brands

A complete trajectory model requires:

• Prior-quarter sales run-rate and regional splits
• Estimated share loss by competitor class
• Net price and rebate curve
• Channel inventory effects

What financial metrics best signal inflection points?

Focus indicators:

• Gross-to-net ratio changes after competitor entry
• Contracting intensity and payer exclusions
• Specialty pharmacy fill rate trends
• Gross sales vs net sales divergence

Key Takeaways

1. EQUIPIN’s market dynamics and financial trajectory are driven by exclusivity/patent timelines, competitor entry speed, and net pricing under payer contracts.
2. A precise exclusivity and litigation-driven forecast requires verified FDA identity data (active ingredient, NDA/BLA, strength/formulation) and Orange Book listing content tied to the actual EQUIPIN product.
3. Generic entry timing and settlement outcomes usually explain the largest share and net price inflections; formulation and method-of-use patents can materially delay or limit label carve-outs.

FAQs

1. How do Orange Book “blocking” patents change generic entry timing for a brand like EQUIPIN?
2. What role do method-of-use patents play in skinny-label acceptance for EQUIPIN?
3. What financial KPIs best indicate approaching generic erosion for an existing pharmaceutical brand?
4. How do payer contracting shifts typically impact net price versus gross sales ahead of patent expiry?
5. What settlement terms most often determine the earliest launch date after a Paragraph IV filing?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
2. FDA. ANDA Litigation and Paragraph IV Certifications. US Food and Drug Administration.
3. FDA. Regulatory Pathways and Exclusivity Guidance. US Food and Drug Administration.